FDA halts trials of Amgen drug in children after 14-year-old dies


The Food and Drug Administration pronounced on Tuesday it has stopped all pediatric clinical trials of Amgen Inc’s Sensipar after a genocide of a 14-year-old studious holding partial in a investigate of a drug.

Sensipar, that is authorized for adults, is used to reduce dangerously high calcium levels in a blood.

The group pronounced it was collecting information on a resources of a teenager’s death. It pronounced it does not know if a Amgen drug had any purpose in a death.

“This communication is dictated to surprise health caring professionals that we are evaluating a information and will promulgate a final conclusions and recommendations when a examination is complete,” a FDA pronounced in a matter posted on a website.

Amgen, a world’s largest biotechnology company, pronounced it had sent a minute final week to medical providers alerting them to a trials’ hindrance and a studious death.

“Amgen is operative as fast as probable to know a resources of what happened. This research is ongoing and will be resolved as fast as possible,” a association pronounced in a statement.

Sensipar works by dwindling a recover of parathyroid hormone from a parathyroid gland to reduce calcium levels in a blood. High levels of calcium in a blood can lead to critical health problems.

Sensipar, that had worldwide sales of $950 million in 2012, is authorized to provide adults 18 and over. The trials were being conducted to establish a reserve and efficiency of a drug in younger patients.

Drugmakers also mostly control pediatric trials since they are rewarded with an additional 6 months of obvious insurance for contrast medicines in children.

  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • BlinkList
  • Digg
  • Google Bookmarks
  • HackerNews
  • Posterous
  • Reddit
  • Sphinn
  • Tumblr
  • Tumblr
  • Tumblr